Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
TRAP feasibility study in resectable HER2-positive esophageal adenocarcinoma
NL-OMON41623Active, not recruiting
- Sponsor
- Amsterdam University Medical Center
- Start
- Apr 2014
- Modality
- Monoclonal Antibodies → Antibody-Based Therapeutics, DNA Intercalators/Alkylators → Nucleic Acid-Directed Small Molecules → Small Molecules, Classical Binding Small Molecules → Small Molecules
- Countries
- 1
01
Overview
Open-label, single-arm trial of trastuzumab, pertuzumab, paclitaxel and carboplatin in esophageal adenocarcinoma (EAC) and gastroesophageal junction adenocarcinoma, sponsored by Amsterdam University Medical Center. Primary endpoint: Feasibility of preoperative treatment in terms of withdrawal rate from surgery. Started Apr 2014; status: active, not recruiting.
02
Drugs
03
Conditions
esophageal adenocarcinoma (EAC)gastroesophageal junction adenocarcinoma
Beyond the preview
Go deeper on NL-OMON41623.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NL-OMON41623.